Stock Events

Stock Events

Hepion Pharmaceuticals 

$0.054375
27
+$0.01+19.37% Friday 18:54

Statistics

Day High
0.06
Day Low
0.0441
52W High
0.11
52W Low
0.033
Volume
71,641
Avg. Volume
28,904
Mkt Cap
631,837.5
P/E Ratio
0.05
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2SepExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-98.5
-65.69
-32.88
-0.07
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-8.28MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HEPA. It's not an investment recommendation.
Apple
6
AAPL
Microsoft
5
MSFT
Tesla
5
TSLA
AT&T
5
T

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences is a leading biopharmaceutical company that develops and markets drugs for life-threatening illnesses including liver disease, a key area of focus for Hepion Pharmaceuticals.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals is involved in creating treatments for serious diseases, including liver diseases, which puts it in direct competition with Hepion Pharmaceuticals' efforts in NASH and liver-related treatments.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.37B
Madrigal Pharmaceuticals focuses on the development of novel therapies for cardiovascular, metabolic, and liver diseases, including NASH, making it a competitor in Hepion's market space.
Viking Therapeutics
VKTX
Mkt Cap4.51B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, positioning it as a competitor to Hepion Pharmaceuticals in the NASH treatment market.
Galmed Pharmaceuticals
GLMD
Mkt Cap4.3M
Galmed Pharmaceuticals is engaged in the development of oral therapies for the treatment of liver diseases, including NASH, competing with Hepion Pharmaceuticals in the liver disease therapeutic area.
Agios Pharmaceuticals
AGIO
Mkt Cap2.45B
Agios Pharmaceuticals focuses on cellular metabolism and rare genetic diseases, including metabolic and liver-related diseases, making it a competitor in the broader market for liver disease treatments.
Enanta Pharmaceuticals
ENTA
Mkt Cap398.37M
Enanta Pharmaceuticals is focused on creating treatments for liver diseases and respiratory infections, with a significant focus on liver diseases, making it a competitor to Hepion.

About

Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Show more...
CEO
Mr. Vincent LoPriore
Employees
2
Country
United States
ISIN
US4268974015

Listings

STU
DE
3360.STU
STU
DE
336N.STU
MU
DE
3360.MU
OTC Link
US
HEPA

0 Comments

Share your thoughts

FAQ

What is Hepion Pharmaceuticals stock price today?▼
The current price of HEPA is $0.05 USD — it has increased by +19.37% in the past 24 hours. Watch Hepion Pharmaceuticals stock price performance more closely on the chart.
What is Hepion Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Hepion Pharmaceuticals stocks are traded under the ticker HEPA.
Is Hepion Pharmaceuticals stock price growing?▼
HEPA stock has fallen by -10.86% compared to the previous week, the month change is a +8.53% rise, over the last year Hepion Pharmaceuticals has showed a -9.37% decrease.
What is Hepion Pharmaceuticals market cap?▼
Today Hepion Pharmaceuticals has the market capitalization of 631,837.5
When is the next Hepion Pharmaceuticals earnings date?▼
Hepion Pharmaceuticals is going to release the next earnings report on September 02, 2026.
What were Hepion Pharmaceuticals earnings last quarter?▼
HEPA earnings for the last quarter are -0.07 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Hepion Pharmaceuticals revenue for the last year?▼
Hepion Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Hepion Pharmaceuticals net income for the last year?▼
HEPA net income for the last year is -8.28M USD.
How many employees does Hepion Pharmaceuticals have?▼
As of July 26, 2026, the company has 2 employees.
In which sector is Hepion Pharmaceuticals located?▼
Hepion Pharmaceuticals operates in the Health & Wellness sector.
When did Hepion Pharmaceuticals complete a stock split?▼
The last stock split for Hepion Pharmaceuticals was on March 18, 2025 with a ratio of 1:50.
Where is Hepion Pharmaceuticals headquartered?▼
Hepion Pharmaceuticals is headquartered in Morristown, United States.